DSIP for Sleep: Research Limits and FDA Status
VA Health & Wellness2 min read
In short
DSIP, or delta sleep-inducing peptide, is also discussed as emideltide. Its name does not establish that a preparation improves restorative sleep or treats insomnia. FDA’s reviewed evidence identifies important effectiveness and safety gaps. A persistent sleep problem deserves a diagnosis and comparison with established care.
On this page
Key takeaways
- What does the name tell you?
It tells you which research substance is being discussed, but it does not tell you whether a clinical outcome has been demonstrated.
- Why does the older research need context?
FDA's 2026 emideltide review discusses small and methodologically limited studies across proposed uses.
- What should be said about FDA status?
DSIP was part of the 2026 compounding review process.
- Why should sleep symptoms be assessed first?
Tell the clinician when the problem started, whether it involves falling asleep or waking, and what happens during the day.
- Which alternatives deserve discussion?
NHLBI describes established insomnia treatment options, including CBT-I.
- Use evidence to guide the next step
Our sleep evidence guide and consultation guide can help organize your questions.
What does the name tell you?
It tells you which research substance is being discussed, but it does not tell you whether a clinical outcome has been demonstrated. Ask the clinician to distinguish the proposed mechanism from an observed benefit. If the claim is deeper sleep, ask which study measured that outcome, what product was administered, and whether the participants resemble patients seeking treatment today.
Why does the older research need context?
FDA's 2026 emideltide review discusses small and methodologically limited studies across proposed uses. It identifies no approved emideltide drug component and missing safety data for the proposed subcutaneous route. [S13] (opens in a new tab) An older intravenous experiment cannot establish the performance of a modern home-injection preparation. The route, study design, and duration should remain part of the explanation rather than disappearing from the summary.
What should be said about FDA status?
DSIP was part of the 2026 compounding review process. An advisory discussion does not confer product approval, and the current codified 503A list retrieved here does not include it. [S08] (opens in a new tab) Its exact ingredient form and applicable current policies need verification before a prescribing discussion becomes a dispensing decision. Avoid calling it an approved sleep therapy based on its name or catalog placement.
Why should sleep symptoms be assessed first?
Tell the clinician when the problem started, whether it involves falling asleep or waking, and what happens during the day. Include medicines and substances you use for sleep, even if purchased without a prescription. A clear history is more informative than a general goal of “better recovery.” Ask whether further assessment is needed before selecting a treatment and whether the problem requires sleep-focused care.
Which alternatives deserve discussion?
NHLBI describes established insomnia treatment options, including CBT-I. [S27] (opens in a new tab) Ask what approach fits the diagnosis and how improvement will be assessed. A plan should account for your schedule, other health conditions, and treatment preferences. Do not assume that a peptide advertised as wellness support has a better risk-benefit balance than conventional care. Comparative claims need comparative evidence.
Use evidence to guide the next step
Our sleep evidence guide and consultation guide can help organize your questions. VA Health & Wellness's care overview explains how to prepare for a provider conversation. This article is educational and does not endorse DSIP for insomnia, narcolepsy, withdrawal treatment, or unsupervised use.
Frequently asked questions
Sources
[S08] eCFR, Office of the Federal Register: 21 CFR 216.23 (opens in a new tab)
[S27] NHLBI, NIH: Insomnia treatment (opens in a new tab)
Related reading
Peptides for Sleep: What the Evidence Can and Cannot Say
October 16, 2026 · 2 min read
Epithalon and Epitalon: Evidence Behind Longevity Claims
October 29, 2026 · 2 min read
Your First Peptide Consultation: How to Prepare